Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Brady, Tyler, Zhang, Tianhui, Tuffy, Kevin M., Haskins, Nantaporn, Du, Qun, Lin, Jia, Kaplan, Gilad, Novick, Steven, Roe, Tiffany L., Ren, Kuishu, Rosenthal, Kim, McTamney, Patrick M., Abram, Michael E., Streicher, Katie, Kelly, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704045/
https://www.ncbi.nlm.nih.gov/pubmed/35993765
http://dx.doi.org/10.1128/spectrum.01034-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704045/
https://www.ncbi.nlm.nih.gov/pubmed/35993765
http://dx.doi.org/10.1128/spectrum.01034-22

Ejemplares similares